At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Doravirine +1 moredrug
Likely dose
Doravirine 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·interventional·Posted Sep 20, 2019·Updated Jul 6, 2022
In Brief
A Phase 2 clinical trial evaluating Doravirine and Descovy for HIV-1-infection. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1-infection
CountriesSpain
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartFeb 2020
Primary CompletionAug 2020
TodayJul 2026
First PostedSep 20, 2019
Enrollment StartFeb 18, 2020
Primary CompletionAug 24, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.8 years ago
Interventions
Doravirinedrug
Doravirine 100 mg tablet
Descovydrug
Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet